tbuckley/cabot-search huggingface dataset:
Correction to: Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS
Authors: Carlos Ferrando, Fernando Suarez-Sipmann, Ricard Mellado-Artigas, María Hernández, Alfredo Gea, Egoitz Arruti, César Aldecoa, Graciela Martínez-Pallí, Miguel A. Martínez-González, Arthur S. Slutsky, Jesús Villar
Journal: Intensive Care Medicine (2020)

The original version of this article unfortunately contained mistakes in Figures 1 and 3.
Abstract 10205: Comparison of the Effects of Bromazepam, Alprazolam and Lorazepam on Noctural Blood Pressure and Heart Rate in Mild Hypertensive Patients
Authors: Roberto Fogari, Alfredo Costa, Angela D’Angelo, Matteo Cotta Ramusino, Daniele Bosone
Journal: Circulation (2019)

Introduction: prevalence of insomnia increases with age and benzodiazepines are the most widely prescribed hypnotic drugs. However, no study to date has evaluated their cardiovascular effects in hy...
Abstract 15951: B-type Natriuretic Peptide and Prognosis of Covid-19 in New York City
Authors: Mai Takahashi, Natalia Egorova, Toshiki Kuno
Journal: Circulation (2020)

Background: The association of B-type natriuretic peptide (BNP) and in-hospital outcomes of Coronavirus disease 2019 (COVID-19) remains unknown. Our aim of this study was to investigate the independent predictors for mortality, especially cardiac history and serial assessment of cardiac markers (B-type natriuretic peptide [BNP] and troponin I). Methods: We obtained the medical records for hospitalized patients with laboratory confirmed COVID-19 from the Mount Sinai Health System. 929 patients with BNP data were divided into 3 groups, BNP ≤ 20 pg/mL, 20 pg/mL &lt; BNP ≤ 100, and 100 pg/mL &lt; BNP. The Cox proportional hazard model was constructed with the three BNP groups and troponin-I, d-dimer and C-reactive protein at admission and peak level. Results: Each BNP category was divided almost equally (BNP ≤ 20 pg/mL (29.9%, N=278), 20 &lt; BNP ≤ 100 pg/mL (35.5%, N= 330), 100 &lt; BNP pg/mL (34.6%, N=321). Patients with high BNP are older and have more co-morbidity including cardiac disease and chronic kidney disease. Patients with high BNP had higher d-dimer, troponin-I than control group. At 4 weeks, death rates were significantly different among the 3 groups (BNP ≤ 20 pg/mL versus 20 &lt; BNP ≤ 100 pg/mL versus 100 &lt; BNP pg/mL: 4.7% versus 13.6% versus 18.4%, P&lt;0.0001). After the Cox model adjustments were done with the initial lab, troponin-I (&gt;0.030 ng/mL) and d-dimer were found to be independent predictors for in-hospital mortality (troponin-I: HR [95%CI]: 1.72 [1.23-2.41], P=0.002), d-dimer: 1.03 [1.00-1.05], P=0.025), but not BNP. Notably, the Cox model with peak lab had better predictability of in-hospital mortality than those with lab at admission. Conclusions: Although higher BNP showed higher in-hospital mortality with unadjusted data with hospitalized COVID-19, BNP was not an independent predictor for in-hospital mortality after adjustment. Serial lab measurements could provide better predictability for in-hospital mortality.
Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus
Authors: Davide Capodanno, Dominick J. Angiolillo
Journal: Circulation (2020)

Patients with diabetes mellitus (DM) are characterized by enhanced thrombotic risk attributed to multiple mechanisms including hyperreactive platelets, hypercoagulable status, and endothelial dysfunction. As such, they are more prone to atherosclerotic cardiovascular events than patients without DM, both before and after coronary artery disease (CAD) is established. In patients with DM without established CAD, primary prevention with aspirin is not routinely advocated because of its increased risk of major bleeding that largely offsets its ischemic benefit. In patients with DM with established CAD, secondary prevention with antiplatelet drugs is an asset of pharmacological strategies aimed at reducing the risk of atherosclerotic cardiovascular events and their adverse prognostic consequences. Such antithrombotic strategies include single antiplatelet therapy (eg, with aspirin or a P2Y 12 inhibitor), dual antiplatelet therapy (eg, aspirin combined with a P2Y 12 inhibitor), and dual-pathway inhibition (eg, aspirin combined with the vascular dose of the direct oral anticoagulant rivaroxaban) for patients with chronic ischemic heart disease, acute coronary syndromes, and those undergoing percutaneous coronary intervention. Because of their increased risk of thrombotic complications, patients with DM commonly achieve enhanced absolute benefit from more potent antithrombotic approaches compared with those without DM, which most often occurs at the expense of increased bleeding. Nevertheless, studies have shown that when excluding individuals at high risk for bleeding, the net clinical benefit favors the use of intensified long-term antithrombotic therapy in patients with DM and CAD. Several studies are ongoing to establish the role of novel antithrombotic strategies and drug formulations in maximizing the net benefit of antithrombotic therapy for patients with DM. The scope of this review article is to provide an overview of current and evolving antithrombotic strategies for primary and secondary prevention of atherosclerotic cardiovascular events in patients with CAD and DM.
Detection of Transvenous Pacemaker and ICD Lead Vegetations: The ICE Cold Facts⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Jayanthi N. Koneru, Kenneth A. Ellenbogen
Journal: Journal of the American College of Cardiology (2013)
Pulmonary surfactant and drug delivery: Vehiculization, release and targeting of surfactant/tacrolimus formulations
Authors: Alberto Hidalgo, Cristina Garcia-Mouton, Chiara Autilio, Pablo Carravilla, Guillermo Orellana, Mohammad N. Islam, Jahar Bhattacharya, Sunita Bhattacharya, Antonio Cruz, Jesús Pérez-Gil
Journal: Journal of Controlled Release (2020)
Diastolic Release of Calcium From the Sarcoplasmic Reticulum: A Potential Target for Treating Triggered Arrhythmias and Heart Failure⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: Thomas R. Shannon, Wilbur Y.W. Lew
Journal: Journal of the American College of Cardiology (2009)
438P Real-world data of relapse after adjuvant treatment (Tx) in high-risk melanoma
Authors: C. Ortiz Velez, G. Villacampa Javierre, E. Zamora, A. Garcia Alvarez, D.G. Illescas, C. Viaplana, M. Batista, M. Martinez, V. Garcia-Patos, D. Bodet-Castillo, B. Ferrer Fabregas, J.A. Recio, J. Hernandez Losa, X. Villalobos Alberú, R. Dienstmann, E. Muñoz-Couselo
Journal: Annals of Oncology (2020)
132P Impact of increasing age on cancer- and noncancer-specific mortality in patients with gastric cancer treated by radical surgery: A competing risk analysis
Authors: L-L. Cao, L-L. Shen, K-X. Xu, J. Lu, C-H. Zheng, P. Li, J-W. Xie, J-B. Wang, J-X. Lin, Q-Y. Chen, M. Lin, R-H. Tu, Z-N. Huang, J-L. Lin, H-L. Zheng, C. Huang
Journal: Annals of Oncology (2020)
13883 Maintenance of response through 136 weeks of long-term continuous risankizumab treatment: An analysis of patients from UltIMMa-1 and UltIMMa-2
Authors: Craig Leonardi, Craig L. Leonardi, Mark Lebwohl, Hervé Bachelez, Kenneth Gordon, Michelle Longcore, Kim Alexander Papp
Journal: Journal of the American Academy of Dermatology (2020)
377O A randomized double-blind phase III study of niraparib versus placebo as maintenance therapy in extensive-stage small cell lung cancer
Authors: X. Ai, Y. Pan, J. Shi, N. Yang, C. Liu, J. Zhou, X. Zhang, X. Dong, J. He, X. Li, G. Chen, X. Li, H. Zhang, W. Liao, Y. Zhang, Z. Ma, B. Zhang, D. Zhang, S. Lu
Journal: Annals of Oncology (2020)
Absolute Myocardial Blood Flow: Emerging Role in Coronary Pathophysiology and Clinical Disease⁎⁎Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.
Authors: Francis J. Klocke, Daniel C. Lee
Journal: JACC. Cardiovascular imaging (2011)
117MO Comparison of survival and patterns of recurrence in gastric neuroendocrine carcinoma, mixed adenoneuroendocrine carcinoma and adenocarcinoma: A multicenter study from China
Authors: J-P. Lin, G-J. Lin, Z-K. Wang, J-X. Lin, C-H. Zheng, P. Li, J-W. Xie, J-B. Wang, J. Lu, Q-Y. Chen, L-L. Cao, M. Lin, R-H. Tu, Z-N. Huang, J-L. Lin, H-L. Zheng, C. Huang
Journal: Annals of Oncology (2020)
Association may be due to imbalance in ratio of adrenal androgens to glucocorticoid
Authors: M J Reed, M W Ghilchik
Journal: BMJ (1996)

accident surveillance scheme.2Last year we re- viewed the data for 1991; we estimate that there were roughly 285 000 new attendances at accident and emergency departments for accidental injuries sustained during leisure activities and 82000 for sporting injuries in Scotland.These represented 24% and 7%, respectively, of all new attendances at accident and emergency departments.The annual direct patient costs associated with sporting injuries
Polyunsaturated Fatty Acids and the Post-Infarct Patient: A Recipe for Baroreflex Health?⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: John Floras, Akshay Bagai
Journal: Journal of the American College of Cardiology (2006)
15950 Tildrakizumab efficacy by metabolic syndrome status in psoriasis: Post hoc analysis of 3-year data from the phase 3 reSURFACE 2 study
Authors: Alice B. Gottlieb, Nehal N. Mehta, Mark Lebwohl, Alan M. Mendelsohn, Jeff Parno, Stephen J. Rozzo, Alan Menter
Journal: Journal of the American Academy of Dermatology (2020)
16317 Characterization of patient clusters based on response to treatment with secukinumab: A “pattern recognition” analysis of pooled phase 3 data
Authors: Kristian Reich, Esteban Daudén, Lorenz Uhlmann, Deborah Keefe, Torben Kasparek, Jennifer Frueh, Marc Vandemeulebroecke, David Demanse
Journal: Journal of the American Academy of Dermatology (2020)
Heterogenous Distribution of Risk for Cardiovascular Disease Events in Patients With Stable Ischemic Heart Disease
Authors: Martin Bødtker Mortensen, Flemming Hald Steffensen, Hans Erik Bøtker, Jesper Møller Jensen, Niels Peter Rønnow Sand, Kristian Hay Kragholm, Helle Kanstrup, Henrik Toft Sørensen, Jonathon Leipsic, Michael J. Blaha, Bjarne Linde Nørgaard
Journal: JACC. Cardiovascular imaging (2020)
15457 Secukinumab significantly improves clinical and patient-reported outcomes up to 18 months of follow-up: Real-world evidence from a US psoriasis registry
Authors: Jerry Bagel, Ajay Behl, Heather J. Litman, Rose A. Medeiros, Ning Guo, Mark Lebwohl, Bruce Strober
Journal: Journal of the American Academy of Dermatology (2020)
13807 Characterization of nonresponders to interleukin-17 inhibitors in moderate to severe psoriasis patients enrolled in the Corrona Psoriasis Registry
Authors: Jashin J. Wu, Tinchi Lin, Donovan G. Kearns, Vipawee S. Chat, Heather J. Litman, Blessing Dube, Robert R. McLean
Journal: Journal of the American Academy of Dermatology (2020)
Cardiac MRI Prediction of Recovery in Children With Acute Myocarditis
Authors: Lamia Ait-Ali, Duarte S. Martins, Diala Khraiche, Pierluigi Festa, Andrea Barison, Nicola Martini, Yasmine Benadjaoud, Rui Anjos, Nathalie Boddaert, Damien Bonnet, Giovanni D. Aquaro, Francesca Raimondi
Journal: JACC. Cardiovascular imaging (2020)
Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy
Authors: Afaf Abed, Leslie Calapre, Johnny Lo, Suzana Correia, Samantha Bowyer, Abha Chopra, Mark Watson, Muhammad Adnan Khattak, Michael Millward, Elin Solomonovna Gray
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background We aimed to assess the impact of genomic human leukocyte antigen (HLA)-I/II homozygosity on the survival benefit of patients with unresectable locally advanced, metastatic non-small lung cancer treated by single-agent programmed cell death protein-1/programmed death ligand 1 (PD1/PDL1) inhibitors. Methods We collected blood from 170 patients with advanced lung cancer treated with immunotherapy at two major oncology centers in Western Australia. Genomic DNA was extracted from white blood cells and used for HLA-I/II high-resolution typing. HLA-I/II homozygosity was tested for association with survival outcomes. Univariable and multivariable Cox regression models were constructed to determine whether HLA homozygosity was an independent prognostic factor affecting Overall Survival (OS) and Progression Free Survival (PFS). We also investigated the association between individual HLA-A and -B supertypes with OS. Results Homozygosity at HLA-I loci, but not HLA-II, was significantly associated with shorter OS (HR=2.17, 95% CI 1.13 to 4.17, p=0.02) in both univariable and multivariable analysis. The effect of HLA-I homozygosity in OS was particularly relevant for patients with tumors expressing PDL1 ≥50% (HR=3.93, 95% CI 1.30 to 11.85, p&lt;0.001). The adverse effect of HLA-I homozygosity on PFS was only apparent after controlling for interactions between PDL1 status and HLA-I genotype (HR=2.21, 95% CI 1.04 to 4.70, p=0.038). The presence of HLA-A02 supertype was the only HLA-I supertype to be associated with improved OS (HR=0.56, 95% CI 0.34 to 0.93, p=0.023). Conclusion Our results suggest that homozygosity at ≥1 HLA-I loci is associated with short OS and PFS in patients with advanced non-small cell lung cancer with PDL1 ≥50% treated with single-agent immunotherapy. Carriers of HLA-A02 supertype reported better survival outcomes in this cohort of patients.
155P Surgical outcomes and technical performance of robotic versus laparoscopic total gastrectomy for gastric cancer: A prospective comparative study FUGES-014
Authors: H-G. Wang, Q. Zhong, S-J. Que, C-H. Zheng, P. Li, J-W. Xie, J-B. Wang, J-X. Lin, J. Lu, Q-Y. Chen, L-L. Cao, M. Lin, R-H. Tu, Z-N. Huang, J-L. Lin, H-L. Zheng, C. Huang
Journal: Annals of Oncology (2020)
225P Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort
Authors: M. Fernando, S. Wong, J. Shapiro, A.J. Weickhardt, L. Spain, A.A. Azad, E. Kwan, A. Muthasamy, J. Torres, P. Parente, F.X. Parnis, J.C.H. Goh, P. Gibbs, B. Tran, A. Anton
Journal: Annals of Oncology (2020)
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Authors: Amita Patnaik, Timothy A. Yap, Hyun Cheol Chung, Maria J. de Miguel, Yung-Jue Bang, Chia-Chi Lin, Wu-Chou Su, Antoine Italiano, Kay Hoong Chow, Anna M. Szpurka, Danni Yu, Yumin Zhao, Michelle Carlsen, Shelly Schmidt, Burkhard Vangerow, Leena Gandhi, Xiaojian Xu, Johanna Bendell
Journal: Clinical Cancer Research (2020)

Abstract Purpose: This phase Ia/Ib PACT study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of a new programmed cell death ligand 1 (PD-L1) inhibitor, LY3300054, as monotherapy or in combination with ramucirumab, abemaciclib, or merestinib (a type II MET kinase inhibitor) in patients with advanced, refractory solid tumors (NCT02791334). Patients and Methods: Patients were enrolled into cohorts of escalating LY3300054 dose (phase Ia) as monotherapy (N = 15) or combined with ramucirumab (N = 10), abemaciclib (N = 24), or merestinib (N = 12). The phase Ib dose expansion enrolled 8 patients with melanoma in the monotherapy arm and 12 patients with pancreatic cancer in the merestinib combination arm. Combination treatments were administered concurrently from day 1 of each cycle. A 14-day lead-in abemaciclib arm was also explored. Primary endpoints were dose-limiting toxicity (DLT) and safety. Results: Treatment-related adverse events included fatigue and nausea in the monotherapy arm (13% for each), hypothyroidism (30%) in the ramucirumab arm, diarrhea (54%) in the abemaciclib arm, and nausea (25%) in the merestinib arm. DLTs associated with hepatoxicity were observed in 3 of 4 patients in the abemaciclib lead-in cohorts. No DLTs or grade 3 or 4 hepatoxicity were reported in the concurrent abemaciclib arm. Pharmacokinetic characteristics were comparable with other PD-L1 inhibitors. One patient in each arm experienced a partial response per RECIST v1.1 lasting ≥7 months. Conclusions: LY3300054 was well tolerated without unexpected safety concerns when administered alone or concurrently with ramucirumab, abemaciclib, or merestinib. Lead-in abemaciclib before combining with LY3300054 was not feasible due to hepatotoxicity. Durable clinical benefits were seen in all regimens.
Quantitative CT Detects Undiagnosed Low Bone Mineral Density in Oncologic Patients Imaged With 18F-FDG PET/CT
Authors: Fernando U. Kay, Vinh Ho, Edmund B. Dosunmu, Avneesh Chhabra, Keenan Brown, Xinhui Duan, Orhan K. Öz
Journal: Clinical Nuclear Medicine (2020)

We assessed the prevalence of low bone mineral density (BMD) in oncologic patients undergoing F-FDG PET/CT.This is a retrospective analysis of 100 patients who underwent F-FDG PET/CT at a single center from October 2015 till May 2016. Quantitative CT (QCT) was used to assess BMD at the lumbar spine (BMDQCT) and femoral necks (BMDCTXA). SUVmax was used to evaluate metabolic activity of the bone marrow. Risk of osteoporosis-related fractures was calculated with femoral neck BMDCTXA and the FRAX algorithm, which was compared against measurements of CT attenuation of the trabecular bone at L1 (L1HU).Osteoporosis and osteopenia were respectively present in 16% and 46% of patients 50 years and older. Bone marrow SUVmax was correlated with BMD at the lumbar spine (ρ = 0.36, P < 0.001). Increased age and low marrow SUVmax were associated with low BMDQCT at the lumbar spine (both P < 0.001), whereas increased age, female sex, and low marrow SUVmax were associated with low BMDCTXA at the femoral necks (P < 0.001, P < 0.001, P = 0.01, respectively). L1HU had an area under the curve of 0.95 (95% confidence interval [CI], 0.90-0.99) for detecting increased risk for osteoporosis-related fracture, with best threshold of 125.8 HU (95% CI, 115.7-144.9) yielding sensitivity of 100% (95% CI, 0.92-1.00), specificity of 0.90 (95% CI, 0.76-0.97), and accuracy of 0.91 (95% CI, 0.79-0.97).Low BMD is frequent in oncologic patients undergoing F-FDG PET/CT. Decreased F-FDG avidity of the bone marrow correlates with decreased BMD, validating the link between osteoporosis and bone marrow fat. L1HU could be a simple and accurate approach for detecting patients at risk for osteoporosis-related fractures using PET/CTdata.
An Intraocular Thymic Metastasis Identified on 18F-FDG PET/CT Before and After Treatment
Authors: Peter J. Brien, Andrew Cha, Michael J. Fulham
Journal: Clinical Nuclear Medicine (2020)

We present the imaging findings pretreatment and posttreatment in a 58-year-old woman with recurrent thymic carcinoma. Two years after treatment, the patient presented with a 3-week history of right eye pain and blurred vision. Ophthalmological examination and MRI of the orbits showed a right superolateral choroidal lesion. Neurologic and whole-body FDG PET/CT scans showed a markedly glucose-avid right choroidal mass and extensive lung parenchymal, pleural, and thoracic nodal disease. There was a good response to chemoradiotherapy with a reduction in size and metabolism at all sites.
Fluid Retention With Thiazolidinediones: Does the Mechanism Influence the Outcome?⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: JoAnn Lindenfeld, Frederick A. Masoudi
Journal: Journal of the American College of Cardiology (2007)
A portable single-sided magnetic-resonance sensor for the grading of liver steatosis and fibrosis
Authors: Ashvin Bashyam, Chris J. Frangieh, Siavash Raigani, Jeremy Sogo, Roderick T. Bronson, Korkut Uygun, Heidi Yeh, Dennis A. Ausiello, Michael J. Cima
Journal: Nature Biomedical Engineering (2020)
An increase in reports of acute flaccid paralysis (AFP) in the United Kingdom, 1 January 2018–21 January 2019: early findings
Journal: Eurosurveillance (2019)

During 2018, the United Kingdom experienced an increase in reports of cases of acute flaccid paralysis (AFP). As at 21 January 2019, 40 cases had been identified with a peak in October 2018. The increase was temporally associated with an upsurge in enterovirus (EV) D68 activity. Enterovirus was detected in 15 cases, mainly from respiratory tract samples; nine were typed as EV-D68. A national task force has been established and investigations are ongoing.
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
Authors: Zoe Boyer-Diaz, Peio Aristu-Zabalza, María Andrés-Rozas, Claude Robert, Martí Ortega-Ribera, Anabel Fernández-Iglesias, Pierre Broqua, Jean-Louis Junien, Guillaume Wettstein, Jaime Bosch, Jordi Gracia-Sancho
Journal: Journal of Hepatology (2020)

In advanced chronic liver disease (ACLD), deregulated hepatic necroinflammatory processes play a key role in the development of liver microvascular dysfunction, fibrogenesis, and increased hepatic vascular tone, resulting in progression of ACLD and portal hypertension. Given the current lack of an effective treatment, we aimed to characterise the effects of the pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist lanifibranor in 2 preclinical models of ACLD, as well as in liver cells from patients with ACLD.Cirrhotic rats (thioacetamide or common bile duct ligation; TAA or cBDL) randomly received lanifibranor (100 mg/kg/day, po) or vehicle for 14 days (n = 12/group). PPAR expression, systemic and hepatic haemodynamics, presence of ascites, liver sinusoidal endothelial cell (LSEC) phenotype, hepatic stellate cell (HSC) activation, serum transaminases and albumin, hepatic macrophage infiltration, cytokine expression, and liver fibrosis were determined. Hepatic cells were isolated from the livers of patients with cirrhosis and their phenotype was evaluated after treatment with either lanifibranor or vehicle.TAA-cirrhotic rats receiving lanifibranor showed significantly lower portal pressure compared with vehicle-treated animals (-15%; p = 0.003) without decreasing portal blood flow, indicating improved hepatic vascular resistance. Moreover, lanifibranor-treated TAA-rats showed decreased ascites, improved LSEC and HSC phenotypes, ameliorated hepatic microvascular function, reduced hepatic inflammation, and significant fibrosis regression (-32%; p = 0.020). These findings were confirmed in the cBDL rat model as well as in human liver cells from patients with cirrhosis, which exhibited phenotypic improvement upon treatment with lanifibranor.Lanifibranor ameliorates fibrosis and portal hypertension in preclinical models of decompensated cirrhosis. Promising results in human hepatic cells further support its clinical evaluation for the treatment of ACLD.Advanced chronic liver disease (ACLD) constitutes a serious public health issue for which safe and effective treatments are lacking. This study shows that lanifibranor improves portal hypertension and liver fibrosis, 2 key elements of the pathophysiology of ACLD, in preclinical models of the disease. Evaluation of lanifibranor in liver cells from patients with ACLD further supports its beneficial effects.
135P Significance of lymphatic invasion in the indication for additional gastrectomy after endoscopic treatment
Authors: H. Fujikawa, T. Yamada, K. Koumori, H. Watanabe, K. Kano, K. Takahashi, Y. Rino, M. Masuda, T. Ogata, T. Oshima
Journal: Annals of Oncology (2020)